Summary
The influence of age on the kinetics of a standard oral dose of levodopa administered with an inhibitor of peripheral dopa decarboxylase enzymes (benserazide) has been evaluated in 40 patients with Parkinson's disease (age 34–78 y) on chronic therapy. They were divided into 2 groups, on the basis of age below (21 patients, Group A) or above (19 patients, Group B) 65 y.
The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 μmol·1−1·min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml·min−1 ·kg−1) and a longer plasma elimination half-life (67.6 versus 54.6 min). The age of the patients was positively correlated with the AUC of levodopa (r=0.474) and its plasma elimination half-life (r=0.391), and was negatively correlated with clearance (r=−0.489).
The findings confirm previous data on volunteers that showed a reduction in the systemic clearance of levodopa due to age, which would probably account for the finding of a greater AUC of levodopa in older patients. The observed, age-mediated differences in levodopa pharmacokinetics, albeit statistically significant, were moderate and were likely to be of only minor importance for the dosing schedule.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nutt JG, Fellmann JH (1984) Pharmacokinetics of levodopa. Clin Neuropharmacol 7: 35–49
Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS (1976) Levodopa and decarboxylase inhibitors: A review of their clinical pharmacology and use in the treatment of Parkinsonism. Drugs 11: 329–377
Evans MA, Triggs EJ, Broe GA, Saines N (1980) Systemic availability of orally administered L-dopa in the elderly Parkinsonian patient. Eur J Clin Pharmacol 17: 215–221
Robertson DRC, Wood ND, Everest H, Monks K, Waller DG, Renwick AG, George CF (1989) The effect of age on the pharmacokinetics of levodopa administered alone and in presence of carbidopa. Br J Clin Pharmacol 28: 61–69
Contin M, Riva R, Martinelli P, Procaccianti G, Cortelli P, Avoni P, Baruzzi A (1990) Response to a standard oral levodopa test in Parkinsonian patients with and without motor fluctuations. Clin Neuropharmacol 13: 19–28
Algeri S, Cerletti C, Curcio M, Morselli PL, Bonolo L, Buniva G, Minazzi M, Minoli G (1976) Effect of anticholinergic drugs on gastrointestinal absorption of L-dopa in rats and in man. Eur J Clin Pharmacol 35: 293–299
Contin M, Riva R, Martinelli P, Procaccianti G, Albani F, Baruzzi A (1991) Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease: effect on levodopa bioavailability. Clin Neuropharmacol 14: 148–155
Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N (1975) Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology 25: 1029–1034
Massoud N (1984) Pharmacokinetic considerations in geriatric patients. In: Benet LZ, Massoud N, Gambertoglio JG (eds) Pharmacokinetic basis for drug treatment. Raven, New York, pp 283–310
Schmucker DL (1985) Aging and drug disposition: an update. Pharmacol Rev 37: 133–148
Pincus JH, Barry K (1987) Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch Neurol 44: 270–272
Baruzzi A, Contin M, Albani F, Riva R (1986) Simple and rapid micromethod for the determination of levodopa and 3-O-methyldopa in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr 375: 165–169
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442
Abrams WB, Coutinho CB, Leon AS, Spiegel HE (1971) Absorption and metabolism of levodopa. JAMA 218: 1912–1914
Andersson I, Granerus AK, Jagenburg R, Svanborg A (1975) Intestinal decarboxylation of orally administered L-dopa. Acta Med Scand 198: 415–420
Cotler S, Holazo A, Boxenbaum HG, Kaplan SA (1976) Influence of route of administration on physiological availability of levodopa in dogs. J Pharm Sci 65: 822–827
Iwamoto K, Watanabe J, Yamada M, Atsumi F, Matsushita T (1987) Effect of age on gastrointestinal and hepatic first-pass effects on levodopa in rats. J Pharm Pharmacol 39: 421–425
Gancher ST, Nutt JG, Woodward WR (1987) Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating Parkinsonian patients. Neurology 37: 940–944
Evans MA, Broe GA, Triggs EJ, Cheung M, Creasey H, Paull PD (1981) Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology 31: 1288–1294
Cedarbaum JM (1987) Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 13: 179–190
Reilly DK, Rivera-Calimlim L, Van Dyke D (1980) Catechol-O-methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther 28: 278–286
Pilling JB, Baker J, Iversen LL, Iversen SD, Robbins T (1975) Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine. J Neurol Neurosurg Psychiat 38: 129–135
Bentué-Ferrer D, Allain H, Reymann JM, Sabouraud O, Van den Driessche J (1988) Lack of pharmacokinetic influence on levodopa by bromocriptine. Clin Neuropharmacol 11: 83–86
Sutton JP, Goetz CG, Buhrfiend C, Carvey PM (1990) Levodopa pharmacokinetics and dopamine agonist cotherapy. Neurology 40 [Suppl 1]: 263
Wilson K (1984) Sex-related differences in drug disposition in man. Clin Pharmacokinet 9: 189–202
Author information
Authors and Affiliations
Additional information
This work was part of the “Progetto finalizzato Invecchiamento” of the National Research Council of Italy, Grant No. 912012
Rights and permissions
About this article
Cite this article
Contin, M., Riva, R., Martinelli, P. et al. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 41, 463–466 (1991). https://doi.org/10.1007/BF00626370
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00626370